Results 31 to 40 of about 177,414 (289)

Neuroenhancement of exposure therapy in anxiety disorders [PDF]

open access: yes, 2015
Although exposure-based treatments and anxiolytic medications are more effective than placebo for treating anxiety disorders, there is still considerable room for further improvement.
Curtiss, Joshua   +2 more
core   +2 more sources

Current status of intestinal transplantation in children [PDF]

open access: yes, 1998
Purpose: A clinical trial of intestinal transplantation (Itx) under tacrolimus and prednisone immunosuppression was initiated in June 1990 in children with irreversible intestinal failure and who were dependent on total parenteral nutrition (TPN ...
Asfar   +52 more
core   +1 more source

Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. [PDF]

open access: yes, 2013
RationaleImpaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive
Acheson, Dean T   +2 more
core   +2 more sources

"All on short" prosthetic-implant supported rehabilitations [PDF]

open access: yes, 2017
Objectives. Short implants are increasing their popularity among clinicians who want to fulfill the constant demanding of fixed prosthetic solutions in edentulous jaws.
Bernardi, S.   +6 more
core   +1 more source

Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know

open access: yesTherapeutic Advances in Chronic Disease, 2021
Management of lung disease in patients with alpha-1 antitrypsin deficiency (AATD) includes both non-pharmacological and pharmacological approaches. Lifestyle changes with avoidance of environmental pollutants, including tobacco smoke, improving exercise ...
Igor Barjaktarevic, Michael Campos
doaj   +1 more source

Frequency and Pattern of Worldwide Ocular Gene Therapy Clinical Trials up to 2022

open access: yesBiomedicines, 2023
The purpose of this study is to describe worldwide gene therapy clinical trials aimed at treating ophthalmic disorders. Information regarding all worldwide clinical trials was collected through 15 different sources, including ClinicalTrials.gov.
Hossein Ameri   +2 more
doaj   +1 more source

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

open access: yesInternational Journal of COPD, 2023
María Torres-Durán,1 José Luis López-Campos,2,3 Myriam Calle Rubio,4 Carmen Montero-Martínez,5 Ana Priegue Carrera,6 Rosanel Amaro Rodríguez,7 Miriam Barrecheguren,8 María Ángeles Barrio Guirado,9 Francisco Javier Callejas-González,10 Francisco Casas ...
Torres-Durán M   +24 more
doaj  

Effect of Membrane Exposure on Guided Bone Regeneration: A Systematic Review and Meta‐Analysis [PDF]

open access: yes, 2018
Aims: This review aimed at investigating the effect of membrane exposure on guided bone regeneration (GBR) outcomes at peri-implant sites and edentulous ridges.
Allen   +70 more
core   +2 more sources

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

open access: yesInternational Journal of COPD, 2020
Franck F Rahaghi,1 Richard Monk,2 Viswanathan Ramakrishnan,3 Tatsiana Beiko,2 Charlie Strange2 1Department of Pulmonary and Critical Care, Cleveland Clinic Florida, Weston, FL, USA; 2Division of Pulmonary, Critical Care, Allergy and Sleep Medicine ...
Rahaghi FF   +4 more
doaj  

A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators [PDF]

open access: yes, 2017
INTRODUCTION: Social anxiety disorder (SAD) is among the most prevalent mental disorders, associated with impaired functioning and poor quality of life. Pharmacotherapy is the most widely utilized treatment option.
Borenstein M   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy